Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion ...Middle East

Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every month First anti-VEGF therapy to achieve non-inferiority in visual acuity gains while doubling the treatment interval in patients with RVO...

Hence then, the article about kodiak sciences reports positive topline results from beacon phase 3 study of tarcocimab tedromer ksi 301 in patients with retinal vein occlusion was published today ( Monday 08/08/2022 - 01:44 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion )

Also on site :

• Werk Room Weekly: Briar Blush faints on-stage, beefs with Mia Starr, more .. ‘Drag Race’ S18 E4 Recap
• Robert Reed’s Daughter, Who Appeared on 'The Brady Bunch', Dies at 69
• ‘Change is inevitable’: What is next for Iran?